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Abstract
Paraneoplastic cerebellar degeneration is part of a rare spectrum of neurological syndromes
whereby gynaecological, lung or breast cancers present primarily with neurological manifestations.
The presence of onconeural antibodies and PET scanning help in the challenging diagnosis of these
conditions but despite the treatment of the primary cancer, the prognosis for the neurological
symptoms is poor.
Background
Paraneoplastic syndromes are non metastatic neurologi-
cal manifestations associated with onconeural antibodies
that arise in less than 1% of patients with an underlying
malignancy. These syndromes are well defined in cases of
small cell carcinoma of the lung and less well known but
described in cases of breast and gynaecological cancers
[1,2]. We present a case of a young woman who presented
with cerebellar signs, positive anti-Yo antibodes and who
was subsequently found to have breast cancer. We also
present a review of the literature and in particular discuss
the treatment options and prognosis of this condition.
Case presentation
The patient was a 40-year-old female who developed dys-
arthria and ataxia in late 2006. These symptoms lasted for
two months after which she made a complete recovery.
Unfortunately she relapsed in March 2007, presenting
with impaired coordination, speech difficulties and ataxia
and was soon after confined to a wheelchair. Breast exam-
ination was normal, and neurological examination con-
firmed the presence of ataxia, dysarthria and impaired
coordination.
MRI scans of the spine and brain were normal and blood
tests were positive for anti-Yo antibodies. A subsequent
whole body PET CT although showed no clear primary
lesion, indicated an avid node in the left axilla. Bilateral
mammograms were normal and ultrasound of both
breasts was normal except for the pathological node in the
left axilla. Fine needle aspiration of the left axillary lymph
node showed metastatic carcinoma, although extensive
immunocytochemical studies could not confirm or
exclude breast or lung carcinoma. MRI scan of the breast
showed a single 6 mm nodular lesion and a targeted ultra-
sound of the left breast showed several hypoechoic nod-
ules. Core biopsies of two of the visualised nodules
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showed high-grade ductal carcinoma in situ and poorly
differentiated invasive carcinoma (Figure 1).
The patient underwent a left skin-sparing mastectomy
combined with implant-based immediate reconstruction
plus axillary node clearance. Histological analysis showed
a 4 cm area of grade 3 invasive ductal carcinoma and DCIS
associated with extensive immunological response that
had broken the tumour into small islands (Figure 1).
There was no lymphovascular invasion, and 3 of 8 lymph
nodes were positive for cancer. The tumour was negative
for oestrogen and progesterone receptors and positive for
HER2.
The patient made a good postoperative recovery and was
subsequently referred for adjuvant chemotherapy and
herceptin treatment and post-mastectomy radiation. Her
neurological condition remained stable during treatment.
Conclusion
Paraneoplastic cerebellar degeneration is classified as one
of the paraneoplastic syndromes. These are rare, non-met-
astatic complications in patients with cancer, commonly
gynaecological, breast or small cell lung in origin.
The pathogenesis of these syndromes is not entirely
understood, but evidence suggests that certain autoanti-
bodies expressed against tumour cells may interact with
cells in the nervous system [1-3]. The anti-Yo group of
antibodies belong to a group of onconeural antibodies,
which are associated with breast, ovarian cancers and
rarely uterine, bronchial or gastric cancers. A small pro-
portion of patients with these malignancies go on to
develop a neurological illness (<1%). Typical manifesta-
tions of this condition include ataxia, resting tremors and
MRI evidence of degeneration and atrophy [4].
Anti-Yo antibodies are anti-Purkinje cell autoantibodies
that act against the antigens common to the tumour and
Purkinje cells in the cerebellum and are produced as an
immune response to some tumours [4]. Not all patients
with paraneoplastic syndromes express antibodies in their
serum. Our patient expressed high titres of anti-Yo anti-
bodies and this feature was reported in 88% of patients
with paraneoplastic cerebellar degeneration [1].
Cases have been reported where cerebellar degeneration
has preceded the tumour by as long as 5 years after expres-
sion of the anit-Yo antibody [5]. As in our case, FDG-PET
has facilitated the early detection of cancer associated
paraneoplastic syndromes [6,7].
Rojas et al evaluated the long-term outcome of PCD and
anti Yo antibodies in 2000. Of a total of 34 patients with
PCD and anti-Yo antibodies, tumour progression was the
cause of death in 52% of cases, whilst in 29% of patients
it was the neurological condition. The failure to cure the
cancer in 52% of patients was due to the fact that by the
time the diagnosis had been made, most tumours had
already metastasised to regional lymph nodes (in our
patient, 4 axillary nodes were positive for malignancy) or
distant organs.
In particular, all patients with breast cancer had axillary
lymph node metastases. This resembles early mediastinal
lymph node metastases in patients with small cell carci-
noma of the lung and anti-Hu associated syndromes. This
suggests that the invasion of the regional nodes causes the
tumour to invoke an immune response, which leads to
the neurological syndromes. Of note, it was found in the
same study, that although anti-Yo antibody associated
syndromes favour the cerebellum, the disease is much
more aggressive with most patients becoming bed bound
within 3 months of the diagnosis [8]. The histological
findings in our case indicate only partial success for the
immune system fighting the primary tumour with no
effect on axillary disease.
Attempts to treat the neurological symptoms on the
whole, using chemotherapy, immunosuppression or
immunoglobulins have not been reported to achieve any
significant improvement [4]. In addition, despite success-
ful treatment of the primary tumour depending on its
stage of development, there is usually no improvement in
the patients' neurological symptoms. These generally have
a greater negative impact on the patients' quality of life
than the underlying malignancy.
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